author_facet Werner, Dominique
Battmann, Achim
Steinmetz, Kristina
Jones, Tobin
Lamb, Tiffany
Martinez, Michele
Al-Batran, Salah-Eddin
Werner, Dominique
Battmann, Achim
Steinmetz, Kristina
Jones, Tobin
Lamb, Tiffany
Martinez, Michele
Al-Batran, Salah-Eddin
author Werner, Dominique
Battmann, Achim
Steinmetz, Kristina
Jones, Tobin
Lamb, Tiffany
Martinez, Michele
Al-Batran, Salah-Eddin
spellingShingle Werner, Dominique
Battmann, Achim
Steinmetz, Kristina
Jones, Tobin
Lamb, Tiffany
Martinez, Michele
Al-Batran, Salah-Eddin
Journal of Clinical Oncology
A novel method combining gene and protein platforms on one slide for the detection of HER2 in gastric cancer: Final results.
Cancer Research
Oncology
author_sort werner, dominique
spelling Werner, Dominique Battmann, Achim Steinmetz, Kristina Jones, Tobin Lamb, Tiffany Martinez, Michele Al-Batran, Salah-Eddin 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2014.32.3_suppl.19 <jats:p> 19 </jats:p><jats:p> Background: The evaluation of gene amplification and/or protein overexpression of HER2 in gastric cancer is a prerequisite to establish an adequate treatment strategy. Gastric tumors are heterogeneous and separate evaluations lead to uncertainties in localizing distinct clones and are time consuming. The aim of this study was to evaluate the feasibility of gene-protein platform in comparison to single staining methods. Methods: Immunohistochemistry (IHC) plus silver in situ hybridization (SISH) (IHC/SISH) and the new gene-protein platform (gene/protein) method for HER2 were performed in randomly collected 100 cases of gastric carcinoma. Evaluation was performed by two observers, in discrepant cases a third observer was consulted to make a decision by consensus. Results of IHC and SISH were compared with gene/protein staining. Rüschoff criteria were applied. Tumors showing HER2 expression 3+ or amplification were considered HER2 positive. Results: 96 of 100 samples were eligible. Amplification was observed in 14.6% by both, conventional SISH and gene/protein platform. 70.8% by IHC and gene/protein had no expression (0) and 10.4%/11.5% (IHC vs. gene/protein) had weak (1+) HER2 expression. Moderate expression (2+) was observed in 9.4% by IHC and 7.3% by gene/protein. Rate of overexpression (3+) was similar in IHC (9.4%) and gene/protein (10.4%). There were complete concordances (100%; κ=1) in IHC assessment of cases with score 0 and SISH amplified tumors. High concordance are shown in score 1+ (98.96%; κ=0.947) and 3+ (96.88%; κ=0.825) cases. Concordance in cases with score 2+ was found in 95.83% (κ=0.728) of the observations. After third observation, there were 5 discordant cases with most discrepancies in assessment of IHC score 2+ or 3+. Conclusions: Gene-protein platform has been tested for first time in gastric carcinoma. Results showed that this novel platform can be a feasible alternative to single methods. Discrepancies in cases with moderate HER2 expression are a result of observer variability. </jats:p> A novel method combining gene and protein platforms on one slide for the detection of HER2 in gastric cancer: Final results. Journal of Clinical Oncology
doi_str_mv 10.1200/jco.2014.32.3_suppl.19
facet_avail Online
Free
finc_class_facet Medizin
format ElectronicArticle
fullrecord blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxNC4zMi4zX3N1cHBsLjE5
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxNC4zMi4zX3N1cHBsLjE5
institution DE-105
DE-14
DE-Ch1
DE-L229
DE-D275
DE-Bn3
DE-Brt1
DE-Zwi2
DE-D161
DE-Gla1
DE-Zi4
DE-15
DE-Rs1
DE-Pl11
imprint American Society of Clinical Oncology (ASCO), 2014
imprint_str_mv American Society of Clinical Oncology (ASCO), 2014
issn 0732-183X
1527-7755
issn_str_mv 0732-183X
1527-7755
language English
mega_collection American Society of Clinical Oncology (ASCO) (CrossRef)
match_str werner2014anovelmethodcombininggeneandproteinplatformsononeslideforthedetectionofher2ingastriccancerfinalresults
publishDateSort 2014
publisher American Society of Clinical Oncology (ASCO)
recordtype ai
record_format ai
series Journal of Clinical Oncology
source_id 49
title A novel method combining gene and protein platforms on one slide for the detection of HER2 in gastric cancer: Final results.
title_unstemmed A novel method combining gene and protein platforms on one slide for the detection of HER2 in gastric cancer: Final results.
title_full A novel method combining gene and protein platforms on one slide for the detection of HER2 in gastric cancer: Final results.
title_fullStr A novel method combining gene and protein platforms on one slide for the detection of HER2 in gastric cancer: Final results.
title_full_unstemmed A novel method combining gene and protein platforms on one slide for the detection of HER2 in gastric cancer: Final results.
title_short A novel method combining gene and protein platforms on one slide for the detection of HER2 in gastric cancer: Final results.
title_sort a novel method combining gene and protein platforms on one slide for the detection of her2 in gastric cancer: final results.
topic Cancer Research
Oncology
url http://dx.doi.org/10.1200/jco.2014.32.3_suppl.19
publishDate 2014
physical 19-19
description <jats:p> 19 </jats:p><jats:p> Background: The evaluation of gene amplification and/or protein overexpression of HER2 in gastric cancer is a prerequisite to establish an adequate treatment strategy. Gastric tumors are heterogeneous and separate evaluations lead to uncertainties in localizing distinct clones and are time consuming. The aim of this study was to evaluate the feasibility of gene-protein platform in comparison to single staining methods. Methods: Immunohistochemistry (IHC) plus silver in situ hybridization (SISH) (IHC/SISH) and the new gene-protein platform (gene/protein) method for HER2 were performed in randomly collected 100 cases of gastric carcinoma. Evaluation was performed by two observers, in discrepant cases a third observer was consulted to make a decision by consensus. Results of IHC and SISH were compared with gene/protein staining. Rüschoff criteria were applied. Tumors showing HER2 expression 3+ or amplification were considered HER2 positive. Results: 96 of 100 samples were eligible. Amplification was observed in 14.6% by both, conventional SISH and gene/protein platform. 70.8% by IHC and gene/protein had no expression (0) and 10.4%/11.5% (IHC vs. gene/protein) had weak (1+) HER2 expression. Moderate expression (2+) was observed in 9.4% by IHC and 7.3% by gene/protein. Rate of overexpression (3+) was similar in IHC (9.4%) and gene/protein (10.4%). There were complete concordances (100%; κ=1) in IHC assessment of cases with score 0 and SISH amplified tumors. High concordance are shown in score 1+ (98.96%; κ=0.947) and 3+ (96.88%; κ=0.825) cases. Concordance in cases with score 2+ was found in 95.83% (κ=0.728) of the observations. After third observation, there were 5 discordant cases with most discrepancies in assessment of IHC score 2+ or 3+. Conclusions: Gene-protein platform has been tested for first time in gastric carcinoma. Results showed that this novel platform can be a feasible alternative to single methods. Discrepancies in cases with moderate HER2 expression are a result of observer variability. </jats:p>
container_issue 3_suppl
container_start_page 19
container_title Journal of Clinical Oncology
container_volume 32
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
_version_ 1792328142303526920
geogr_code not assigned
last_indexed 2024-03-01T12:48:34.108Z
geogr_code_person not assigned
openURL url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=A+novel+method+combining+gene+and+protein+platforms+on+one+slide+for+the+detection+of+HER2+in+gastric+cancer%3A+Final+results.&rft.date=2014-01-20&genre=article&issn=1527-7755&volume=32&issue=3_suppl&spage=19&epage=19&pages=19-19&jtitle=Journal+of+Clinical+Oncology&atitle=A+novel+method+combining+gene+and+protein+platforms+on+one+slide+for+the+detection+of+HER2+in+gastric+cancer%3A+Final+results.&aulast=Al-Batran&aufirst=Salah-Eddin&rft_id=info%3Adoi%2F10.1200%2Fjco.2014.32.3_suppl.19&rft.language%5B0%5D=eng
SOLR
_version_ 1792328142303526920
author Werner, Dominique, Battmann, Achim, Steinmetz, Kristina, Jones, Tobin, Lamb, Tiffany, Martinez, Michele, Al-Batran, Salah-Eddin
author_facet Werner, Dominique, Battmann, Achim, Steinmetz, Kristina, Jones, Tobin, Lamb, Tiffany, Martinez, Michele, Al-Batran, Salah-Eddin, Werner, Dominique, Battmann, Achim, Steinmetz, Kristina, Jones, Tobin, Lamb, Tiffany, Martinez, Michele, Al-Batran, Salah-Eddin
author_sort werner, dominique
container_issue 3_suppl
container_start_page 19
container_title Journal of Clinical Oncology
container_volume 32
description <jats:p> 19 </jats:p><jats:p> Background: The evaluation of gene amplification and/or protein overexpression of HER2 in gastric cancer is a prerequisite to establish an adequate treatment strategy. Gastric tumors are heterogeneous and separate evaluations lead to uncertainties in localizing distinct clones and are time consuming. The aim of this study was to evaluate the feasibility of gene-protein platform in comparison to single staining methods. Methods: Immunohistochemistry (IHC) plus silver in situ hybridization (SISH) (IHC/SISH) and the new gene-protein platform (gene/protein) method for HER2 were performed in randomly collected 100 cases of gastric carcinoma. Evaluation was performed by two observers, in discrepant cases a third observer was consulted to make a decision by consensus. Results of IHC and SISH were compared with gene/protein staining. Rüschoff criteria were applied. Tumors showing HER2 expression 3+ or amplification were considered HER2 positive. Results: 96 of 100 samples were eligible. Amplification was observed in 14.6% by both, conventional SISH and gene/protein platform. 70.8% by IHC and gene/protein had no expression (0) and 10.4%/11.5% (IHC vs. gene/protein) had weak (1+) HER2 expression. Moderate expression (2+) was observed in 9.4% by IHC and 7.3% by gene/protein. Rate of overexpression (3+) was similar in IHC (9.4%) and gene/protein (10.4%). There were complete concordances (100%; κ=1) in IHC assessment of cases with score 0 and SISH amplified tumors. High concordance are shown in score 1+ (98.96%; κ=0.947) and 3+ (96.88%; κ=0.825) cases. Concordance in cases with score 2+ was found in 95.83% (κ=0.728) of the observations. After third observation, there were 5 discordant cases with most discrepancies in assessment of IHC score 2+ or 3+. Conclusions: Gene-protein platform has been tested for first time in gastric carcinoma. Results showed that this novel platform can be a feasible alternative to single methods. Discrepancies in cases with moderate HER2 expression are a result of observer variability. </jats:p>
doi_str_mv 10.1200/jco.2014.32.3_suppl.19
facet_avail Online, Free
finc_class_facet Medizin
format ElectronicArticle
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
geogr_code not assigned
geogr_code_person not assigned
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxNC4zMi4zX3N1cHBsLjE5
imprint American Society of Clinical Oncology (ASCO), 2014
imprint_str_mv American Society of Clinical Oncology (ASCO), 2014
institution DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Rs1, DE-Pl11
issn 0732-183X, 1527-7755
issn_str_mv 0732-183X, 1527-7755
language English
last_indexed 2024-03-01T12:48:34.108Z
match_str werner2014anovelmethodcombininggeneandproteinplatformsononeslideforthedetectionofher2ingastriccancerfinalresults
mega_collection American Society of Clinical Oncology (ASCO) (CrossRef)
physical 19-19
publishDate 2014
publishDateSort 2014
publisher American Society of Clinical Oncology (ASCO)
record_format ai
recordtype ai
series Journal of Clinical Oncology
source_id 49
spelling Werner, Dominique Battmann, Achim Steinmetz, Kristina Jones, Tobin Lamb, Tiffany Martinez, Michele Al-Batran, Salah-Eddin 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2014.32.3_suppl.19 <jats:p> 19 </jats:p><jats:p> Background: The evaluation of gene amplification and/or protein overexpression of HER2 in gastric cancer is a prerequisite to establish an adequate treatment strategy. Gastric tumors are heterogeneous and separate evaluations lead to uncertainties in localizing distinct clones and are time consuming. The aim of this study was to evaluate the feasibility of gene-protein platform in comparison to single staining methods. Methods: Immunohistochemistry (IHC) plus silver in situ hybridization (SISH) (IHC/SISH) and the new gene-protein platform (gene/protein) method for HER2 were performed in randomly collected 100 cases of gastric carcinoma. Evaluation was performed by two observers, in discrepant cases a third observer was consulted to make a decision by consensus. Results of IHC and SISH were compared with gene/protein staining. Rüschoff criteria were applied. Tumors showing HER2 expression 3+ or amplification were considered HER2 positive. Results: 96 of 100 samples were eligible. Amplification was observed in 14.6% by both, conventional SISH and gene/protein platform. 70.8% by IHC and gene/protein had no expression (0) and 10.4%/11.5% (IHC vs. gene/protein) had weak (1+) HER2 expression. Moderate expression (2+) was observed in 9.4% by IHC and 7.3% by gene/protein. Rate of overexpression (3+) was similar in IHC (9.4%) and gene/protein (10.4%). There were complete concordances (100%; κ=1) in IHC assessment of cases with score 0 and SISH amplified tumors. High concordance are shown in score 1+ (98.96%; κ=0.947) and 3+ (96.88%; κ=0.825) cases. Concordance in cases with score 2+ was found in 95.83% (κ=0.728) of the observations. After third observation, there were 5 discordant cases with most discrepancies in assessment of IHC score 2+ or 3+. Conclusions: Gene-protein platform has been tested for first time in gastric carcinoma. Results showed that this novel platform can be a feasible alternative to single methods. Discrepancies in cases with moderate HER2 expression are a result of observer variability. </jats:p> A novel method combining gene and protein platforms on one slide for the detection of HER2 in gastric cancer: Final results. Journal of Clinical Oncology
spellingShingle Werner, Dominique, Battmann, Achim, Steinmetz, Kristina, Jones, Tobin, Lamb, Tiffany, Martinez, Michele, Al-Batran, Salah-Eddin, Journal of Clinical Oncology, A novel method combining gene and protein platforms on one slide for the detection of HER2 in gastric cancer: Final results., Cancer Research, Oncology
title A novel method combining gene and protein platforms on one slide for the detection of HER2 in gastric cancer: Final results.
title_full A novel method combining gene and protein platforms on one slide for the detection of HER2 in gastric cancer: Final results.
title_fullStr A novel method combining gene and protein platforms on one slide for the detection of HER2 in gastric cancer: Final results.
title_full_unstemmed A novel method combining gene and protein platforms on one slide for the detection of HER2 in gastric cancer: Final results.
title_short A novel method combining gene and protein platforms on one slide for the detection of HER2 in gastric cancer: Final results.
title_sort a novel method combining gene and protein platforms on one slide for the detection of her2 in gastric cancer: final results.
title_unstemmed A novel method combining gene and protein platforms on one slide for the detection of HER2 in gastric cancer: Final results.
topic Cancer Research, Oncology
url http://dx.doi.org/10.1200/jco.2014.32.3_suppl.19